$2,500,000 Operating Bridge

Summary of Indicative Terms · Trocar Pharma, Inc. · RadShield™ (YK-4-250)

Trocar Pharma is raising an immediate $2,500,000 bridge to reopen and scale operations, rebuild the full-time team, and complete the development and regulatory work required to enter its $37,500,000 and $50,000,000 follow-on tranches from strength.

Terms of the Offering

Issuer	Trocar Pharma, Inc., a Maryland C-Corporation
Lead Asset	RadShield™ (YK-4-250) — first-in-class oral mitigator of Gastrointestinal Acute Radiation Syndrome (GI-ARS)
Offering	$2,500,000 operating bridge — open now
Exemption	Regulation D, Rule 506(c) — verified accredited investors only
Security	Convertible note or preferred equity (final terms set with counsel at closing)
Minimum Investment	$25,000; larger allocations welcome
Closing Mechanics	Rolling closings so capital funds operations before the round is fully subscribed
Subscription Window	60 days from launch
Verification	Third-party accreditation verification required under Rule 506(c)
Escrow	Subscription funds held in third-party escrow pending closing conditions
Investor Priority	Bridge participants are offered allocation in both follow-on tranches
Follow-On Tranche 1	$37,500,000 — IND enablement; opens upon achievement of bridge milestones
Follow-On Tranche 2	$50,000,000 — Phase 1/2 and procurement readiness; opens on IND clearance
Governing Documents	Private Placement Memorandum, subscription agreement and related governing documents
Jurisdiction	Maryland corporate law; offering conducted in permitted U.S. jurisdictions

Use of Bridge Proceeds

Category	Amount	Share
Core payroll & benefits	$750,000	30%
Product / CMC completion	$750,000	30%
Regulatory, quality & clinical planning	$375,000	15%

Lab & preclinical studies	$250,000	10%
Legal, financing & compliance	$125,000	5%
Business development & investor relations	$125,000	5%
Contingency / working capital	$125,000	5%
Total	$2,500,000	100%

Why This Bridge, Now

- 88% survival at 14.3 Gy versus 58% control in DoD/AFRRI GI-ARS studies.
- $4.5M+ of DoD/AFRRI preclinical funding already deployed — government-generated data.
- FDA Pre-IND complete; Animal Rule pathway (21 CFR §314.610) confirmed.
- Georgetown University Exclusive License No. 2022-0493 and four U.S. patents.
- Zero FDA-approved therapies for the early lethal GI effects of radiation exposure.
- Oral, 24-hour post-exposure window; tablet or suspension, non-clinical administration.

Contact

TriUnity Capital Ventures, LLC · 6345 S. Pecos Rd., Suite 109, Las Vegas, NV 89120
invest@trocarpharma.finance · info@trocarpharma.finance · 702-929-9226